– Highly-Specific Allosteric ACLY Inhibitor Designed to Target Liver and Bile Duct Injury, Inflammation, and Fibrosis Associated with Primary Sclerosing Cholangitis (PSC) and Related Diseases – – ...

Dewpoint has selected a novel small molecule to prevent the formation of abnormal TDP-43 protein clumps in ALS and other ...

MP0726, a Radio-DARPin candidate targeting mesothelin (MSLN) and intended for the treatment of ovarian cancer, is nominated for development under strategic partnership with Orano Med Promising tumor ...

RJVA-002 achieved ~30% weight loss at five weeks in a translational obesity model; weight loss not yet plateaued Preclinical results show that a single point-in-time treatment with RJVA-002 has the ...

The collaboration marks a turning point in AI-driven drug design and trial forecasting, de-risking the drug development ...

Molecular Partners AG and Orano Med have announced the development of MP0726, a Radio-DARPin candidate targeting mesothelin (MSLN) for ovarian cancer treatment, which shows promising tumor ...

Research Provides Early Validation of ALLO-182, an AlloCAR T™ Candidate in the IND-Enabling Phase of Development Targeting Claudin18.2 for the Treatment of Patients with Gastric and Pancreatic Cancers ...

– Presentation highlights in vitro activity across a spectrum of clinically-relevant variants as well as in vivo reduction of body weight and hyperphagia in MC4R-deficient Mutant Mice – "We're ...

Aera Therapeutics, a biotechnology company harnessing next-generation enabling delivery technologies and precision payloads to unlock the full potential of genetic medicines, today presented ...

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) is one of the best performing pharma stocks in 2025. Amylyx Pharmaceuticals, Inc. ...

FT819 continues to demonstrate meaningful decrease in disease and favorable safety profile with twelve systemic lupus erythematosus (SLE) patients now treated; first systemic sclerosis (SSc) patient ...